Please use this identifier to cite or link to this item:
Title: Outcomes of non-myeloablative allogeneic stem cell transplant in older patients with acute myeloid leukaemia in first remission.
Austin Authors: Nguyen, Phillip C;Manos, Kate ;Fong, Chun Y;Schwarer, Anthony P ;Tiong, Ing S ;Wei, Andrew H;Kliman, David;Curtis, David J
Affiliation: Department of Clinical Haematology, Alfred Health, Melbourne, Victoria, Australia
Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia
Department of Clinical Haematology, Box Hill Hospital, Melbourne, Victoria, Australia
Clinical Haematology
Issue Date: 2021
Publication information: Internal medicine journal 2021; 51(11): 1954-1958
Abstract: The benefits of non-myeloablative stem cell transplant in older patients with acute myeloid leukaemia are unclear. We compare the long-term outcomes of this regimen in those aged 55-65 years in first remission with a chemotherapy only cohort that achieved durable morphologic remission. Five-year overall survival was similar (32% vs 33%, P = 0.90), as was relapse-free survival (23% vs 20%, P = 0.37). There was a trend for decreased relapse that was balanced against increased non-relapse mortality with transplantation.
DOI: 10.1111/imj.15564
ORCID: 0000-0002-6238-0681
Journal: Internal Medicine Journal
PubMed URL: 34796631
PubMed URL: 10.1111/imj.15564 Abstract
Type: Journal Article
Subjects: acute myeloid leukemia
consolidation chemotherapy
haemopoietic stem cell transplantation
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Apr 20, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.